Application of surface area measurement for identifying the source of batch-to-batch variation in processability Extent of amorphous content by BET surface area R.R. Vippagunta et al.

Pharmaceutical Development and Technology

Volumn 14, Issue 5, 2009, Pages 492-498

  Vippagunta, Radha R ^a   Pan, Changkang ^a   Vakil, Ronak ^a   Meda, Vindhya ^a   Vivilecchia, Richard ^a   Motto, Michael ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

BET equation; Quantifying amorphous content; Specific surface area; Water sorption

Indexed keywords

ARTICLE; CONTROLLED STUDY; CRYSTAL; DRUG FORMULATION; MATERIALS TESTING; PRIORITY JOURNAL; SURFACE PROPERTY; WATER ABSORPTION;

CALORIMETRY, DIFFERENTIAL SCANNING; CRYSTALLIZATION; DRUG COMPOUNDING; SURFACE PROPERTIES; TABLETS; WATER; X-RAY DIFFRACTION;

EID: 70350647619     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.1080/10837450902763007     Document Type: Article

References (21)

1. Vachon MG, Chulia D. The use of energy indices in estimating powder compaction functionality of mixtures in pharmaceutical tableting. Int J Pharm 1999;117:163-200.
2. Joneja SK, Harcum WW, Skinner GW, Barnum PE, Guo JH. Investigating the fundamental effects of binders on Pharmaceutical Tablets Performance. Drug Dev Ind Pharm 1999;25(10):1129-1135.
3. Brunauer S, Emmett PH, Teller E. Absorption of gases in multimolecular layers. J Am Chem Soc 1938;60:309.
4. Briggner L-E, Buckton G, Bystrom K, Darcy P. The use of isothermal microcalorimetry in the study of changes in crystallinity induced during the processing of powders. Int J Pharm 1994;105:125-135.
5. Brodka-Pfeiffer K, Langguth P, Grass P, Hausler H., Influence of mechanical activation on the physical stability of salbutamol sulphate. Eur J Pharm Biopharm 2003;56:393-400.
6. Feeley JC, York P, Sumby BS, Dicks H. Determination of surface properties and flow characteristics of salbutamol sulphate, before and after micronization. Int J Pharm 1998;172:89-96.
7. Feeley JC, York P, Sumby BS, Dicks H. Processing effects on the surface properties of alpha-lactose monohydrate assesses by inverse gas chromatography (IGC). J Mater Sci 2002;37:217-222.
8. Zhou D, Zhang GGZ, Law D, Grant DJW, Schmitt EA. Physical stability of amorphous pharmaceuticals: Importance of con- figurational thermodynamic quantities and molecular mobility. J Pharm Sci 2002;19(8):1863-1872.
9. Hancock BC, Carlson GT, Ladipo DD, Langdon BA, Mullarney MP. Comparison of the mechanical properties of the crystalline and amorphous forms of a drug substance. Int J Pharm 2002;241:73-85.
10. Fix I, Steffens KJ. Quantifying low amorphous or crystalline amounts of alpha-lactose-monohydrate using X-ray powder diffraction, near-infrared spectroscopy, and differential scanning calorimetry. Drug Dev Ind Pharm 2004;30(5):513-523.
11. Byard SJ, Jackson SL, Smail A, Bauer M, Apperley DC. Studies on the crystallinity of a pharmaceutical development drug substance. J Pharm Sci 2005;94:1321-1335.
12. Sebbatu T, Angberg M, Ahlneck C. Assessment of degree of disorder in crystalline solids by isothermal microcalorimetry. Int J Pharm 1994;104:135-144.
13. Giron D, Remy P, Thomas S, Vilette E. Quantitation of amorphicity by microcalorimetry. J Therm Anal 1997;48:465-472.
14. Venkatesh GM, Barnett ME, Owusu-Fordjour C, Galop M. Detection of low levels of the amorphous phase in crystalline pharmaceutical materials by thermally stimulated current spectrometry. Pharm Res 2001;18:98-103.
15. Taylor LS, Zografi G. The quantitative analysis of crystallinity using FT-Raman spectroscopy. Pharm Res 1998;15:755-761.
16. Bertacche V, Pini E, Stradi R, Stratta F. Quantitative determination of amorphous cyclosporine in crystalline cyclosporine samples by Fourier transform infrared spectroscopy. J Pharm Sci 2006;95:159-166.
17. Hogan SE, Buckton G. The application of near infrared spectroscopy and dynamic vapor sorption to quantify low amorphous contents of crystalline lactose. Pharm Res 2001;18:112-116.
18. Saleki-Gerhardt A, Ahlneck C, Zografi G. Assessment of disorder in crystalline solids. Int J Pharm 1994;101:237-247.
19. Carvajal MT, Staniforth JN. Interactions of water with the surfaces of crystal polymorphs. Int J Pharm 2006;307:216-224.
20. Mackin L, Sartnurak S, Thomas I, Moore S. The impact of low levels of amorphous material (< 5%) on the blending characteristics of a direct compression formulation. Int J Pharm, 2002, 231:213-226.
21. Mackin L, Zanon R, Park JM, Foster K, Opalenik H, Demonte M.Quantification of low levels (< 10%) of amorphous content in isothermal microcalorimetry. Int J Pharm 2002;231:227-236.